Episode 49 - Podcast: Bispecific Antibodies Across Targets: Practical Integration in RRMM - Part 3 of RRMM Podcasts: Practical Insights for the First Relapse

Managing relapsed/refractory multiple myeloma (RRMM), particularly at first relapse, requires timely, evidence-based decisions in an increasingly complex treatment landscape. As therapeutic options continue to expand and clinical guidance evolves, healthcare professionals must navigate challenges related to risk stratification, treatment selection, sequencing strategies, and the integration of emerging immunotherapies into practice.

Clinicians may also face uncertainty in distinguishing mechanisms of action, managing immune-related toxicities, and selecting appropriate therapies in the context of treatment resistance. Additionally, real-world barriers such as staffing shortages, infusion capacity constraints, and workflow demands can complicate the implementation of optimal care. This podcast series features expert-led conversations that deliver practical insights and real-world strategies to support confident, guideline-informed decision-making in the management of RRMM.

Launch Date/Release: July 2, 2026

Expiration Date: August 31, 2027

FACULTY

Ajai Chari, MD

Professor of Clinical Medicine

University of California, San Francisco

Sagar Lonial, MD, FACP, FASCO

Chair and Professor

Department of Hematology and Medical Oncology

Anne and Bernard Gray Family Chair in Cancer

Chief Medical Officer

Winship Caner Institute | Emory University

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.